New Risk • Jul 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). High level of non-cash earnings (32% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹336, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 605% over the past three years. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹262, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 360% over the past three years. Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹20.48 (vs ₹9.32 in FY 2025) Full year 2026 results: EPS: ₹20.48 (up from ₹9.32 in FY 2025). Revenue: ₹6.51b (up 8.5% from FY 2025). Net income: ₹661.3m (up 117% from FY 2025). Profit margin: 10% (up from 5.1% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 06
Wanbury Limited to Report Q4, 2026 Results on May 14, 2026 Wanbury Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 14, 2026 Reported Earnings • Feb 09
Third quarter 2026 earnings released: EPS: ₹4.52 (vs ₹0.38 in 3Q 2025) Third quarter 2026 results: EPS: ₹4.52 (up from ₹0.38 in 3Q 2025). Revenue: ₹1.62b (up 22% from 3Q 2025). Net income: ₹157.6m (up ₹145.4m from 3Q 2025). Profit margin: 9.7% (up from 0.9% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 78% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 38% After last week's 38% share price gain to ₹258, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 501% over the past three years. Announcement • Jan 29
Wanbury Limited to Report Q3, 2026 Results on Feb 05, 2026 Wanbury Limited announced that they will report Q3, 2026 results on Feb 05, 2026 New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹6.46b market cap, or US$70.2m). Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹180, the stock trades at a trailing P/E ratio of 12.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 311% over the past three years. Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹4.58 (vs ₹2.44 in 2Q 2025) Second quarter 2026 results: EPS: ₹4.58 (up from ₹2.44 in 2Q 2025). Revenue: ₹1.60b (flat on 2Q 2025). Net income: ₹151.8m (up 89% from 2Q 2025). Profit margin: 9.5% (up from 5.0% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 08
Wanbury Limited to Report Q2, 2026 Results on Nov 13, 2025 Wanbury Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Announcement • Aug 25
Wanbury Limited, Annual General Meeting, Sep 18, 2025 Wanbury Limited, Annual General Meeting, Sep 18, 2025, at 11:30 Indian Standard Time. Location: ebony hall, hotel tunga regenza, plot no. 37, sector 30-a, opp. vashi railway station, maharashtra - 4000703, vashi India Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹301, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 407% over the past three years. Reported Earnings • Aug 05
First quarter 2026 earnings released: EPS: ₹4.12 (vs ₹0.32 in 1Q 2025) First quarter 2026 results: EPS: ₹4.12 (up from ₹0.32 in 1Q 2025). Revenue: ₹1.64b (up 25% from 1Q 2025). Net income: ₹134.9m (up ₹124.5m from 1Q 2025). Profit margin: 8.2% (up from 0.8% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 56% per year, which means it is well ahead of earnings. Announcement • Jul 29
Wanbury Limited to Report Q1, 2026 Results on Aug 04, 2025 Wanbury Limited announced that they will report Q1, 2026 results at 3:30 PM, Indian Standard Time on Aug 04, 2025 New Risk • Jul 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.36b (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Earnings have declined by 0.2% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (5.1% net profit margin). Market cap is less than US$100m (₹8.36b market cap, or US$96.8m). New Risk • May 17
New major risk - Revenue and earnings growth Earnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 0.2% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (5.1% net profit margin). Reported Earnings • May 17
Full year 2025 earnings released: EPS: ₹9.32 (vs ₹17.10 in FY 2024) Full year 2025 results: EPS: ₹9.32 (down from ₹17.10 in FY 2024). Revenue: ₹6.03b (up 4.8% from FY 2024). Net income: ₹305.3m (down 45% from FY 2024). Profit margin: 5.1% (down from 9.7% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 68% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹278, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 317% over the past three years. Announcement • May 10
Wanbury Limited to Report Q4, 2025 Results on May 15, 2025 Wanbury Limited announced that they will report Q4, 2025 results on May 15, 2025 Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹237, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 193% over the past three years. New Risk • Apr 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹265, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 207% over the past three years. Board Change • Mar 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Vice Chairman Krishnamoorthy Chandran is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹171, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 111% over the past three years. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹0.38 (vs ₹3.14 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.38 (down from ₹3.14 in 3Q 2024). Revenue: ₹1.34b (down 7.7% from 3Q 2024). Net income: ₹12.2m (down 88% from 3Q 2024). Profit margin: 0.9% (down from 7.1% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹242, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 157% over the past three years. Announcement • Feb 08
Wanbury Limited to Report Q3, 2025 Results on Feb 12, 2025 Wanbury Limited announced that they will report Q3, 2025 results on Feb 12, 2025 New Risk • Jan 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.25b (US$96.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). High level of non-cash earnings (66% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹8.25b market cap, or US$96.1m). Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹252, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 215% over the past three years. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹271, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 211% over the past three years. New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). High level of non-cash earnings (66% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Announcement • Dec 06
Wanbury Limited Announces Retirement of Pravin Dilip Pawar as Independent Director Wanbury Limited announced that Mr. Pravin Dilip Pawar retired from the position of the Independent Directors on completion of his First term of Office as an position of the Independent Directors on completion of his First term of Office as an 17th November, 2024 and ceased to be the Independent Director of the Company thereafter. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹272, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 224% over the past three years. Announcement • Nov 21
Pravin Dilip Pawar Retires from the Position of the Independent Directors on Completion of First Term of Office as an Independent Director of Wanbury Limited Wanbury Limited informed that Mr. Pravin Dilip Pawar (DIN: 10356479) retired from the position of the Independent Directors on completion of his First term of Office as an Independent Director of the Company with effect from closing of the business hours on 17th November, 2024 and ceased to be the Independent Director of the Company thereafter. Reported Earnings • Nov 18
Second quarter 2025 earnings released: EPS: ₹2.44 (vs ₹2.25 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.44 (up from ₹2.25 in 2Q 2024). Revenue: ₹1.63b (up 13% from 2Q 2024). Net income: ₹80.2m (up 8.9% from 2Q 2024). Profit margin: 4.9% (down from 5.1% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 06
Wanbury Limited to Report Q2, 2025 Results on Nov 13, 2024 Wanbury Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Sep 12
Wanbury Limited Informs About Its New Products Launch Wanbury Limited informed about its new products launch, its commercialization and pipeline as under: API: Metformin HCl. Therapeutic Area: Anti-Diabetic. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):61,400. API: Sertraline HCl. Therapeutic Area: Anti - depressant. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):650. API: Diphenhydramine HCl. Therapeutic Area: Anti-histamine. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):291. API: Diphenhydramine Citrate. Therapeutic Area: Anti-histamine. Pharmacopeial Details: USP. USDMF: Y. CEP: NA. Global Demand (MT):291. API: Tramadol HCl. Therapeutic Area: Analgesic. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):556. API: Paroxetine HCl. Therapeutic Area: Anti - depressant. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):68. API: Mefenamic Acid. Therapeutic Area: Anti - Inflammatory. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):1,469. New APIs to be launched in FY24- 5: API: Dextromethorphan H r. Therapeutic Area: Antitussives. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: Y. Global Demand (MT):209. API: Ketamine HCl. Therapeutic Area: Anaesthetic. Pharmacopeial Details: USP, Ph.Eur, BP, and IP. USDMF: Y. CEP: under filing. Global Demand (MT):4. API Product Pipeline: API: Rivaroxaban. Therapeutic Area: Anti- Coagulant. Current Status: Tech pack available. Global Demand (MT): 65. API: Quetiapine Fumarate. Therapeutic Area: Atypical antipsychotics. Current Status: USDMF Filed. Global Demand (MT): 675. API: Montelukast Sodium. Therapeutic Area: Antiteukotriene Anti-Asthmatics. Current Status: Plant Validation by Dec'24. Global Demand (MT):82. API: Imeglimin HCl. Therapeutic Area: Anti- Diabetic. Current Status: Plant Validation by Q1’25. Global Demand (MT): 101. API: Sitagliptin Phosphate Monohydrate. Therapeutic Area: Anti- Diabetic. Current Status: Plant validation by Dec’24. Global Demand (MT): 609. Announcement • Aug 30
Wanbury Limited, Annual General Meeting, Sep 27, 2024 Wanbury Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time. Announcement • Aug 22
Wanbury Limited Announces Appointment of Pradeep Patni as CEO of India Formulation Business Wanbury Limited announced the appointment of Mr. Pradeep Patni as CEO of India Formulation Business. Mr. Patni brings over 25 years of distinguished experience in the pharmaceutical industry, having most recently served as CEO at Akumentis. During his 4 - year tenure (FY21-24) at Akumentis, Mr. Patni, along with the leadership team, drove remarkable growth in sales, which increased by 1.7 times from INR 2330 million in FY21 to INR 3980 million in FY24. Additionally, the EBITDA margin improved significantly, rising from 4% in FY21 to 21 % in FY24. An MBA from IIM Bangalore, Mr. Patni has a rich background in managing independent business units within leading multinational pharmaceutical corporations. His broad expertise spans both patented and generic molecules, as well as bio-therapeutics, enabling him to navigate diverse markets and portfolios effectively. Throughout his career, Mr. Patni has consistently delivered on organizational objectives. Mr. Patni, began his career at Ranbaxy Labs and has since built a successful professional trajectory in the pharmaceutical industry, having worked with companies such as Janssen (10 years), Pfizer Ltd. (6 years), Abbott Healthcare (6 years) and Micro Labs. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹209, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 151% over the past three years. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.32 (vs ₹1.43 in 1Q 2024) First quarter 2025 results: EPS: ₹0.32 (down from ₹1.43 in 1Q 2024). Revenue: ₹1.32b (down 9.7% from 1Q 2024). Net income: ₹10.4m (down 78% from 1Q 2024). Profit margin: 0.8% (down from 3.2% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 06
Wanbury Limited to Report Q1, 2025 Results on Aug 12, 2024 Wanbury Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹193, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 124% over the past three years. New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₹5.17b market cap, or US$62.0m). Reported Earnings • May 18
Full year 2024 earnings released: EPS: ₹17.10 (vs ₹3.18 loss in FY 2023) Full year 2024 results: EPS: ₹17.10 (up from ₹3.18 loss in FY 2023). Revenue: ₹5.79b (up 16% from FY 2023). Net income: ₹559.6m (up ₹663.5m from FY 2023). Profit margin: 9.7% (up from net loss in FY 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • May 09
Wanbury Limited to Report Q4, 2024 Results on May 16, 2024 Wanbury Limited announced that they will report Q4, 2024 results on May 16, 2024 Board Change • Apr 12
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Director Pravin Pawar was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹163, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹127, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 59% over the past three years. Announcement • Feb 21
Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director Wanbury Limited announced that Ms. Pallavi Prakash Shedge are retired from the position of the Independent Directors on completion of her second term of Office as an Independent Director of the Company with effect from closing of the business hours on 13th February, 2024 and ceased to be the Independent Director of the Company thereafter. Reported Earnings • Jan 25
Third quarter 2024 earnings released: EPS: ₹3.14 (vs ₹1.00 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹3.14 (up from ₹1.00 loss in 3Q 2023). Revenue: ₹1.46b (up 16% from 3Q 2023). Net income: ₹102.7m (up ₹135.5m from 3Q 2023). Profit margin: 7.0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Announcement • Jan 13
Wanbury Limited to Report Q3, 2024 Results on Jan 24, 2024 Wanbury Limited announced that they will report Q3, 2024 results on Jan 24, 2024 Announcement • Nov 19
Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director Wanbury Limited announced that at its EGM held on 18 November 2023 have approved the appointment of Mr. Pravin Dilip Pawar as the non-executive independent director of the company for a term of one year with effect from November 18, 2023 to November 17, 2024. Mr. Pravin Dilip Pawar holds a master's degree in commerce. He is a qualified Chartered Accountant from the ICAI. Reported Earnings • Oct 21
Second quarter 2024 earnings released: EPS: ₹2.25 (vs ₹0.27 loss in 2Q 2023) Second quarter 2024 results: EPS: ₹2.25 (up from ₹0.27 loss in 2Q 2023). Revenue: ₹1.45b (up 17% from 2Q 2023). Net income: ₹73.6m (up ₹82.5m from 2Q 2023). Profit margin: 5.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Announcement • Oct 13
Wanbury Limited to Report Q2, 2024 Results on Oct 20, 2023 Wanbury Limited announced that they will report Q2, 2024 results on Oct 20, 2023 New Risk • Sep 11
New major risk - Negative shareholders equity The company has negative equity. Total equity: -₹328m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Negative equity (-₹328m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₹2.16b market cap, or US$26.0m). Announcement • Aug 31
Wanbury Limited, Annual General Meeting, Sep 27, 2023 Wanbury Limited, Annual General Meeting, Sep 27, 2023, at 11:30 Indian Standard Time. Announcement • Aug 22
Wanbury Limited Appoints Mohan Kumar Rayana as Whole Time Director Wanbury Limited at its Extra Ordinary General Meeting held on August 21, 2023, appointed Mr. Mohan Kumar Rayana as Whole Time Director. Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: ₹1.43 (vs ₹2.22 loss in 1Q 2023) First quarter 2024 results: EPS: ₹1.43 (up from ₹2.22 loss in 1Q 2023). Revenue: ₹1.47b (up 26% from 1Q 2023). Net income: ₹46.9m (up ₹119.3m from 1Q 2023). Profit margin: 3.2% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Announcement • Aug 03
Wanbury Limited to Report Q1, 2024 Results on Aug 11, 2023 Wanbury Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Reported Earnings • Jul 08
Full year 2023 earnings released: ₹3.18 loss per share (vs ₹25.29 profit in FY 2022) Full year 2023 results: ₹3.18 loss per share (down from ₹25.29 profit in FY 2022). Revenue: ₹5.01b (down 2.1% from FY 2022). Net loss: ₹104.0m (down 113% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹53.45, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 163% over the past three years. Announcement • May 23
Wanbury Limited to Report Q4, 2023 Results on May 30, 2023 Wanbury Limited announced that they will report Q4, 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹42.80, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 85% over the past three years. Reported Earnings • Feb 16
Third quarter 2023 earnings released: ₹1.00 loss per share (vs ₹0.12 profit in 3Q 2022) Third quarter 2023 results: ₹1.00 loss per share (down from ₹0.12 profit in 3Q 2022). Revenue: ₹1.26b (up 1.0% from 3Q 2022). Net loss: ₹32.8m (down ₹36.5m from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 14% per year and the company’s share price has also increased by 14% per year. Announcement • Feb 04
Wanbury Limited to Report Q3, 2023 Results on Feb 14, 2023 Wanbury Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 30
Second quarter 2023 earnings released: ₹0.27 loss per share (vs ₹0.17 loss in 2Q 2022) Second quarter 2023 results: ₹0.27 loss per share (further deteriorated from ₹0.17 loss in 2Q 2022). Revenue: ₹1.25b (flat on 2Q 2022). Net loss: ₹8.90m (loss widened 53% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹51.60, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 168% over the past three years. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment improved over the past week After last week's 17% share price gain to ₹69.90, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 436% over the past three years. Reported Earnings • Aug 12
First quarter 2023 earnings released: ₹2.22 loss per share (vs ₹0.28 loss in 1Q 2022) First quarter 2023 results: ₹2.22 loss per share (down from ₹0.28 loss in 1Q 2022). Revenue: ₹1.19b (down 7.0% from 1Q 2022). Net loss: ₹72.4m (loss widened ₹63.8m from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹72.50, the stock trades at a trailing P/E ratio of 2.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 407% over the past three years. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 20% share price gain to ₹68.05, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 384% over the past three years. Reported Earnings • Jun 24
Full year 2022 earnings released: EPS: ₹25.29 (vs ₹5.04 loss in FY 2021) Full year 2022 results: EPS: ₹25.29 (up from ₹5.04 loss in FY 2021). Net income: ₹814.7m (up ₹940.8m from FY 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.12 (down from ₹2.36 in 3Q 2021). Revenue: ₹1.25b (up 14% from 3Q 2021). Net income: ₹3.74m (down 94% from 3Q 2021). Profit margin: 0.3% (down from 5.4% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 27
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: ₹0.17 loss per share (down from ₹0.65 profit in 2Q 2021). Revenue: ₹1.24b (up 30% from 2Q 2021). Net loss: ₹5.82m (down 136% from profit in 2Q 2021). Revenue was in line with analyst estimates. 
